The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Measuring Hepatitis C Virus Elimination as a Public Health Threat: Beyond Global Targets
J Viral Hepat. 2020 Mar 18. doi: 10.1111/jvh.13294. Online ahead of print.
Daniela K van Santen 1 2 3, Rachel Sacks-Davis 1 3, Joseph S Doyle 1 4, Nick Scott 1 3, Maria Prins 2 5, Margaret Hellard 1 4 6
Author information
1Department of Disease Elimination, Burnet Institute, Melbourne, VIC, Australia.
2Department of Infectious Disease Research and Prevention, Public Health Service of Amsterdam, Amsterdam, The Netherlands.
3School of Population Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
4Department of Infectious Diseases, The Alfred and Monash University, Melbourne, VIC, Australia.
5Amsterdam UMC, University of Amsterdam, Department of Infectious Diseases, Amsterdam Infection and Immunity Institute (AI&II), Amsterdam, The Netherlands.
6Doherty Institute and Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia.
Abstract
An increasing number of countries are committing to meet the World Health Organization (WHO) targets to eliminate hepatitis C virus (HCV) as a public health threat by 2030. These include service coverage targets (90% diagnosed and 80% of diagnosed patients treated) and impact targets (80% and 65% reductions in incidence and mortality, respectively, compared to 2015 levels). Currently, a dozen countries are on track to reach 2030 WHO HCV targets. However, while striving for the WHO targets is important, it should be recognized that progress on impact targets is derived from mathematical models projecting decreases in incidence and mortality on a global scale. Despite HCV treatment access in many counties for a number of years, limited empirical data are available to evaluate progress towards elimination. In some countries, substantial incidence and mortality reductions based on reaching the WHO service coverage targets may be unachievable. For example, in countries with ageing hepatitis C-infected populations, even if they have a quality hepatitis C response, high hepatitis C-related morbidity at baseline may not be reversible even with increased HCV treatment uptake and diagnosis. Finally, WHO targets are not necessarily easily or reliably measurable. Measuring relative impact targets requires high-quality data at baseline (ie 2015) and longitudinal data to assess temporal trends. In this commentary, we propose alternative additional measures to track progress on reducing the HCV burden, offer examples where the WHO targets may not be informative or achievable, and potential practical solutions.